Drug interactions
Deferasirox + Paclitaxel protein bound
Severity: Major
Deferasirox and Paclitaxel protein bound: major interaction.
Last updated Sources: US FDA label
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Deferasirox inhibits CYP2C8, which clears paclitaxel, and may raise paclitaxel exposure and increase myelosuppression and neuropathy. It may also weakly induce CYP3A4, but the net effect is expected to be an increase.
What this interaction means in plain words
Deferasirox and Paclitaxel protein bound can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Deferasirox inhibits CYP2C8-mediated paclitaxel metabolism, with a possible opposing weak CYP3A4 induction.
What to do
Avoid concurrent use if possible; otherwise monitor blood counts and neuropathy closely and consider reducing the paclitaxel dose.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Paclitaxel protein bound, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
References
Other interactions of Deferasirox
Frequently asked questions
Can I take Deferasirox with Paclitaxel protein bound?
MediHelp rates the interaction as major. Deferasirox and Paclitaxel protein bound can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Deferasirox inhibits CYP2C8, which clears paclitaxel, and may raise paclitaxel exposure and increase myelosuppression and neuropathy. It may also weakly induce CYP3A4, but the net effect is expected to be an increase.
How serious is the interaction between Deferasirox and Paclitaxel protein bound?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use if possible; otherwise monitor blood counts and neuropathy closely and consider reducing the paclitaxel dose.
What other medicines interact with Deferasirox?
MediHelp also lists interactions of Deferasirox with, for example, Acetylsalicylic acid, Alosetron, Aluminum hydroxide. The full list is on the Deferasirox page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
